Translational advances in multiple myeloma: β-adrenergic blockade and strategies to overcome metabolite-driven resistance to BCL-2 antagonists

 Host

Cristina João, MD, PhD, Myeloma Lymphoma Lab

Venue

Seminar Room

Abstract

Altered cellular metabolism can support cancer cell survival and contribute to therapeutic resistance. This colloquium will explore translational strategies targeting these vulnerabilities, focusing on β-adrenergic blockade and approaches to overcome metabolite-driven resistance to BCL-2 antagonists. Drawing on research in multiple myeloma, the presentation will discuss the relationship between metabolism, mitochondrial function and apoptotic sensitivity, and its implications for developing more effective cancer therapies.

Bio

Dr. Malathy (“Mala”) Shanmugam is an Associate Professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine and a member of the Winship Cancer Institute. She obtained her MS in Biotechnology from Madurai Kamaraj University, India, and her PhD in Tumor Cell Biology from Northwestern University Medical School, followed by fellowship training at Northwestern and Loyola University Chicago Medical Center. Her research investigates how altered metabolism and mitochondrial function influence cancer cell survival, treatment resistance and invasion, with the aim of identifying metabolic vulnerabilities that can be targeted therapeutically.

Register here.

About CR Colloquia Series

Champalimaud Research (CR) Colloquia Series is a seminar programme organised by the Champalimaud Centre for the Unknown to promote the discussion about the most interesting and significant questions in neuroscience and physiology & cancer with appointed speakers by the CR Community.